ePrints

Just so stories: The random acts of anti-cancer nanomedicine performance

Lookup NU author(s): Professor Moein MoghimiORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© 2014 Elsevier Inc.Contrary to high expectations, the majority of clinically approved anti-cancer nanomedicine, and those under clinical trials, have shown limited therapeutic efficacy in humans. So, why these nanomedicine are not delivering their promise? Here, we discuss likely factors, and call for a paradigm shift in approach and design of future cancer nanotherapeutics based on realistic cancer models representing human disease, and better understanding of integrated pathophysiological processes, including systems immunology, that modulate human tumor functionality and growth. From the Clinical Editor: This critical review of the current state of translational oncology research utilizing nanomedicine-based approaches provides a comprehensive discussion of the multiple factors that are responsible for poor outcomes when translating these approaches models to the actual human disease.

Publication metadata

Author(s): Moghimi SM, Farhangrazi ZS

Publication type: Article

Publication status: Published

Journal: Nanomedicine: Nanotechnology, Biology, and Medicine

Year: 2014

Volume: 10

Issue: 8

Pages: 1661-1666

Print publication date: 01/11/2014

Online publication date: 14/05/2014

Acceptance date: 29/04/2014

ISSN (print): 1549-9634

ISSN (electronic): 1549-9642

Publisher: Elsevier Inc.

URL: https://doi.org/10.1016/j.nano.2014.04.011

DOI: 10.1016/j.nano.2014.04.011

PubMed id: 24832960

Altmetrics

Share